Drugs / Prevnar 20
Prevnar 20
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07712575 | Aug 2026 → Jun 2028 expected | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05412030 | Jun 2022 → Sep 2025 | streptococcal pneumonia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05170399 | Sep 2022 → Aug 2026 overdue | lymphoma | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT07168915 Comparator | Oct 2025 → Jul 2027 expected | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06611033 Comparator | Sep 2024 → Jan 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT06790290 Comparator | Jan → Apr 2025 overdue | pneumococcal infection | Inventprise Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05297578 Comparator | Jun 2022 → Feb 2023 | — | Vaxcyte, Inc. | Completed | Met primary |
| Phase 3 | NCT07160244 Background | Aug 2025 → Nov 2028 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT06824194 Comparator | Feb 2025 → Oct 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06736041 Comparator | Dec 2024 → May 2027 expected | — | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03621670 Background | Jul 2018 → Dec 2024 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prevnar 20 | “0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1” NCT05297578 ↗ |
| Known as | PCV13 | “Prevnar 20 (PCV13) was administered intramuscularly as a booster dose on Day 301 group who have received 3 PCV13 doses before 12 months of age but have not received their...” NCT03621670 ↗ |
| Known as | Prevnar 20, PCV20 | “Prevnar 20, PCV20” NCT05297578 ↗ |
| Modality | Vaccine | “Pneumococcal 20-Valent Conjugate Vaccine (PCV20)” NCT05170399 ↗ |
| Route | Intramuscular | “Prevnar 20 (PCV13) was administered intramuscularly as a booster dose on Day 301 group who have received 3 PCV13 doses before 12 months of age but have not received their...” NCT03621670 ↗ |